Published in Mol Cell Biol on December 01, 2002
Targeting the TGFβ signalling pathway in disease. Nat Rev Drug Discov (2012) 4.30
TGF-beta switches from tumor suppressor to prometastatic factor in a model of breast cancer progression. J Clin Invest (2003) 3.01
A crucial role of caspase-3 in osteogenic differentiation of bone marrow stromal stem cells. J Clin Invest (2004) 1.71
Targeting the transforming growth factor-beta signaling pathway in human cancer. Expert Opin Investig Drugs (2010) 1.57
National Cancer Institute pediatric preclinical testing program: model description for in vitro cytotoxicity testing. Pediatr Blood Cancer (2010) 1.47
Glucocorticoids and histone deacetylase inhibitors cooperate to block the invasiveness of basal-like breast cancer cells through novel mechanisms. Oncogene (2012) 1.14
Growth factors and myometrium: biological effects in uterine fibroid and possible clinical implications. Hum Reprod Update (2011) 1.10
Rapamycin-induced G1 cell cycle arrest employs both TGF-β and Rb pathways. Cancer Lett (2015) 0.96
TIGAR induces p53-mediated cell-cycle arrest by regulation of RB-E2F1 complex. Br J Cancer (2012) 0.93
A novel class of cyclin-dependent kinase inhibitors identified by molecular docking act through a unique mechanism. J Biol Chem (2009) 0.90
Identification of genes, including the gene encoding p27Kip1, regulated by serine 276 phosphorylation of the p65 subunit of NF-kappaB. Cancer Lett (2008) 0.87
Transforming growth factor-beta induces Cdk2 relocalization to the cytoplasm coincident with dephosphorylation of retinoblastoma tumor suppressor protein. Breast Cancer Res (2004) 0.86
Assembly, activation, and substrate specificity of cyclin D1/Cdk2 complexes. Biochemistry (2013) 0.83
Constitutive Cdk2 activity promotes aneuploidy while altering the spindle assembly and tetraploidy checkpoints. J Cell Sci (2013) 0.82
Elevated cutaneous Smad activation associates with enhanced skin tumor susceptibility in organ transplant recipients. Clin Cancer Res (2009) 0.81
Rapamycin sensitizes Akt inhibition in malignant human breast epithelial cells. Cancer Lett (2010) 0.79
(-)-Oleocanthal rapidly and selectively induces cancer cell death via lysosomal membrane permeabilization. Mol Cell Oncol (2015) 0.78
Novel agents that downregulate EGFR, HER2, and HER3 in parallel. Oncotarget (2015) 0.77
CUB domain-containing protein 1 and the epidermal growth factor receptor cooperate to induce cell detachment. Breast Cancer Res (2016) 0.77
Signaling mechanisms that suppress the cytostatic actions of rapamycin. PLoS One (2014) 0.75
Cancer cell cycles. Science (1996) 21.29
Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. Nucleic Acids Res (1990) 20.53
A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature (1994) 11.50
Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science (1991) 10.16
Direct binding of Smad3 and Smad4 to critical TGF beta-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene. EMBO J (1998) 10.01
Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell (1996) 8.77
RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs. Cell (1994) 8.71
MYC oncogenes and human neoplastic disease. Oncogene (1999) 7.28
Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin. Science (1997) 7.07
Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci U S A (2001) 6.99
An assay for transforming growth factor-beta using cells transfected with a plasminogen activator inhibitor-1 promoter-luciferase construct. Anal Biochem (1994) 6.31
Interleukin-2-mediated elimination of the p27Kip1 cyclin-dependent kinase inhibitor prevented by rapamycin. Nature (1994) 5.12
The E2F1-3 transcription factors are essential for cellular proliferation. Nature (2001) 4.37
Blocking oncogenic Ras signaling for cancer therapy. J Natl Cancer Inst (2001) 4.25
Repression of p15INK4b expression by Myc through association with Miz-1. Nat Cell Biol (2001) 4.22
Centrosome duplication in mammalian somatic cells requires E2F and Cdk2-cyclin A. Nat Cell Biol (1999) 3.74
TGFbeta influences Myc, Miz-1 and Smad to control the CDK inhibitor p15INK4b. Nat Cell Biol (2001) 3.69
E1A-dependent trans-activation of the human MYC promoter is mediated by the E2F factor. Proc Natl Acad Sci U S A (1989) 3.67
Suppression of tumorigenicity of human prostate carcinoma cells by replacing a mutated RB gene. Science (1990) 3.58
TGF-beta 1 inhibition of c-myc transcription and growth in keratinocytes is abrogated by viral transforming proteins with pRB binding domains. Cell (1990) 3.55
Destruction of Myc by ubiquitin-mediated proteolysis: cancer-associated and transforming mutations stabilize Myc. EMBO J (1999) 3.50
Growth factors and cancer. Cancer Res (1986) 3.48
Cyclin D expression is controlled post-transcriptionally via a phosphatidylinositol 3-kinase/Akt-dependent pathway. J Biol Chem (1998) 3.25
Integrin beta 1 signaling is necessary for transforming growth factor-beta activation of p38MAPK and epithelial plasticity. J Biol Chem (2001) 3.04
Transforming growth factor beta-induced phosphorylation of Smad3 is required for growth inhibition and transcriptional induction in epithelial cells. Proc Natl Acad Sci U S A (1997) 2.97
Myc and Ras collaborate in inducing accumulation of active cyclin E/Cdk2 and E2F. Nature (1997) 2.78
p107 uses a p21CIP1-related domain to bind cyclin/cdk2 and regulate interactions with E2F. Genes Dev (1995) 2.60
Defective repression of c-myc in breast cancer cells: A loss at the core of the transforming growth factor beta growth arrest program. Proc Natl Acad Sci U S A (2001) 2.55
Point mutations in the c-Myc transactivation domain are common in Burkitt's lymphoma and mouse plasmacytomas. Nat Genet (1993) 2.47
Efficient screening of retroviral cDNA expression libraries. Proc Natl Acad Sci U S A (1995) 2.46
TOR mutations confer rapamycin resistance by preventing interaction with FKBP12-rapamycin. J Biol Chem (1995) 2.39
c-Myc in breast cancer. Endocr Relat Cancer (2000) 2.32
Transforming growth factor-beta1 is a new form of tumor suppressor with true haploid insufficiency. Nat Med (1998) 2.29
mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. Endocr Relat Cancer (2001) 2.26
Concern Direct interaction of c-Myc with Smad2 and Smad3 to inhibit TGF-beta-mediated induction of the CDK inhibitor p15(Ink4B). Mol Cell (2002) 2.09
c-Myc hot spot mutations in lymphomas result in inefficient ubiquitination and decreased proteasome-mediated turnover. Blood (2000) 2.08
Mammary tumor suppression by transforming growth factor beta 1 transgene expression. Proc Natl Acad Sci U S A (1995) 2.07
Mechanism of TGFbeta receptor inhibition by FKBP12. EMBO J (1997) 2.06
Nuclear localization of p85s6k: functional requirement for entry into S phase. EMBO J (1994) 2.06
Site-specific modulation of c-Myc cotransformation by residues phosphorylated in vivo. Oncogene (1994) 2.05
TbetaR-I(6A) is a candidate tumor susceptibility allele. Cancer Res (1999) 1.99
The immunophilin FKBP12 functions as a common inhibitor of the TGF beta family type I receptors. Cell (1996) 1.99
Inhibition of the phosphoinositide 3-kinase pathway induces a senescence-like arrest mediated by p27Kip1. J Biol Chem (2000) 1.88
Rapamycin inhibition of the G1 to S transition is mediated by effects on cyclin D1 mRNA and protein stability. J Biol Chem (1998) 1.86
Cdk2 kinase is required for entry into mitosis as a positive regulator of Cdc2-cyclin B kinase activity. Cell (1996) 1.84
Expression of the E2F1 transcription factor overcomes type beta transforming growth factor-mediated growth suppression. Proc Natl Acad Sci U S A (1995) 1.81
c-myc is a downstream target of the Smad pathway. J Biol Chem (2001) 1.74
A new pathway for mitogen-dependent cdk2 regulation uncovered in p27(Kip1)-deficient cells. Curr Biol (1999) 1.70
Regulation of cell growth and cyclin D1 expression by the constitutively active FRAP-p70s6K pathway in human pancreatic cancer cells. Cancer Res (1999) 1.67
Transforming growth factors and control of neoplastic cell growth. J Cell Biochem (1987) 1.67
Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition. Clin Cancer Res (2001) 1.65
Expression of dominant-negative mutant DP-1 blocks cell cycle progression in G1. Mol Cell Biol (1996) 1.62
Translational induction of the c-myc oncogene via activation of the FRAP/TOR signalling pathway. Oncogene (1998) 1.62
A role for transcriptional repression of p21CIP1 by c-Myc in overcoming transforming growth factor beta -induced cell-cycle arrest. Proc Natl Acad Sci U S A (2000) 1.61
A link between increased transforming activity of lymphoma-derived MYC mutant alleles, their defective regulation by p107, and altered phosphorylation of the c-Myc transactivation domain. Mol Cell Biol (1995) 1.59
Myc downregulation by transforming growth factor beta required for activation of the p15(Ink4b) G(1) arrest pathway. Mol Cell Biol (1999) 1.57
FRAP/mTOR is required for proliferation and patterning during embryonic development in the mouse. Proc Natl Acad Sci U S A (2001) 1.48
Role of transforming growth factor beta in cancer. J Cell Physiol (2001) 1.46
ErbB2/neu kinase modulates cellular p27(Kip1) and cyclin D1 through multiple signaling pathways. Cancer Res (2001) 1.44
Overexpression of the c-Myc oncoprotein blocks the growth-inhibitory response but is required for the mitogenic effects of transforming growth factor beta 1. Proc Natl Acad Sci U S A (1995) 1.43
Early gene responses to transforming growth factor-beta in cells lacking growth-suppressive RB function. Mol Cell Biol (1991) 1.43
Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy. Cancer Res (2001) 1.41
Studies on the mechanism of resistance to rapamycin in human cancer cells. Mol Pharmacol (1998) 1.41
Clustered mutations in the second exon of the MYC gene in sporadic Burkitt's lymphoma. Oncogene (1993) 1.39
Mitogenic conversion of transforming growth factor-beta1 effect by oncogenic Ha-Ras-induced activation of the mitogen-activated protein kinase signaling pathway in human prostate cancer. Cancer Res (2000) 1.33
p130 and p107 use a conserved domain to inhibit cellular cyclin-dependent kinase activity. Mol Cell Biol (1997) 1.31
TGF beta in prostate cancer: a growth inhibitor that can enhance tumorigenicity. Prostate (1997) 1.30
Stem cell factor/c-kit up-regulates cyclin D3 and promotes cell cycle progression via the phosphoinositide 3-kinase/p70 S6 kinase pathway in spermatogonia. J Biol Chem (2000) 1.29
Three distinct elements within the murine c-myc promoter are required for transcription. Oncogene (1992) 1.21
FKBP12, the 12-kDa FK506-binding protein, is a physiologic regulator of the cell cycle. Proc Natl Acad Sci U S A (2001) 1.19
Transforming growth factor beta regulation of cell proliferation. J Cell Physiol Suppl (1987) 1.18
Factor-binding element in the human c-myc promoter involved in transcriptional regulation by transforming growth factor beta 1 and by the retinoblastoma gene product. Proc Natl Acad Sci U S A (1991) 1.18
Disruption of TGF-beta growth inhibition by oncogenic ras is linked to p27Kip1 mislocalization. Oncogene (2000) 1.12
Transforming growth factor beta targeted inactivation of cyclin E:cyclin-dependent kinase 2 (Cdk2) complexes by inhibition of Cdk2 activating kinase activity. Proc Natl Acad Sci U S A (1999) 1.09
E2F4-RB and E2F4-p107 complexes suppress gene expression by transforming growth factor beta through E2F binding sites. Proc Natl Acad Sci U S A (1997) 1.05
TGF-beta1 effects on proliferation of rat intestinal epithelial cells are due to inhibition of cyclin D1 expression. Oncogene (1998) 1.04
Release from G1 growth arrest by transforming growth factor beta 1 requires cellular ras activity. J Biol Chem (1993) 1.04
A role for a p21-E2F interaction during senescence arrest of normal human fibroblasts. Cell Growth Differ (1996) 0.99
Transforming growth factor beta 1 regulation of c-myc expression, pRB phosphorylation, and cell cycle progression in keratinocytes. Cell Growth Differ (1992) 0.99
Characterization of the interaction of FKBP12 with the transforming growth factor-beta type I receptor in vivo. J Biol Chem (1996) 0.98
NF-kappa B is required for H-ras oncogene induced abnormal cell proliferation and tumorigenesis. Oncogene (2000) 0.93
Transforming growth factor-beta receptors on human endometrial cells: identification of the type I, II, and III receptors and glycosyl-phosphatidylinositol anchored TGF-beta binding proteins. Mol Cell Endocrinol (1995) 0.90
TGF-beta-signaling with small molecule FKBP12 antagonists that bind myristoylated FKBP12-TGF-beta type I receptor fusion proteins. Chem Biol (1998) 0.90
Alterations of the retinoblastoma gene in human prostate adenocarcinoma. Genes Chromosomes Cancer (1996) 0.88
Tumorigenic transformation of NIH 3T3 cells by the autocrine synthesis of transforming growth factor alpha. New Biol (1991) 0.86
Inhibition of DNA synthesis by a farnesyltransferase inhibitor involves inhibition of the p70(s6k) pathway. J Biol Chem (1999) 0.84
Insensitivity to growth inhibition by TGF-beta1 correlates with a lack of inhibition of the CDK2 activity in prostate carcinoma cells. Oncogene (1998) 0.83
Salicylate-induced growth arrest is associated with inhibition of p70s6k and down-regulation of c-myc, cyclin D1, cyclin A, and proliferating cell nuclear antigen. J Biol Chem (2000) 0.82
The effect of H-ras oncogene transfection on response of mink lung epithelial cells to growth factors and cytotoxic drugs. Anticancer Res (1991) 0.76
Stromal fibroblasts in cancer initiation and progression. Nature (2004) 11.69
TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science (2004) 10.23
Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer. Nat Rev Cancer (2006) 8.59
Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell (2008) 6.78
Blockade of TGF-beta inhibits mammary tumor cell viability, migration, and metastases. J Clin Invest (2002) 4.64
TGF-beta and cancer. Cytokine Growth Factor Rev (2005) 3.38
Conditional inactivation of the TGF-beta type II receptor using Cre:Lox. Genesis (2002) 3.21
Aggressive pancreatic ductal adenocarcinoma in mice caused by pancreas-specific blockade of transforming growth factor-beta signaling in cooperation with active Kras expression. Genes Dev (2006) 3.16
Tumor-stroma interactions. Curr Opin Genet Dev (2005) 2.89
Conditional inactivation of Tgfbr2 in cranial neural crest causes cleft palate and calvaria defects. Development (2003) 2.78
Effect of conditional knockout of the type II TGF-beta receptor gene in mammary epithelia on mammary gland development and polyomavirus middle T antigen induced tumor formation and metastasis. Cancer Res (2005) 2.63
TGF-beta and immune cells: an important regulatory axis in the tumor microenvironment and progression. Trends Immunol (2010) 2.61
Activation of the Erk pathway is required for TGF-beta1-induced EMT in vitro. Neoplasia (2004) 2.60
Inhibiting Cxcr2 disrupts tumor-stromal interactions and improves survival in a mouse model of pancreatic ductal adenocarcinoma. J Clin Invest (2011) 2.54
Inhibition of TGF-beta with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression. J Clin Invest (2007) 2.52
CD36 repression activates a multicellular stromal program shared by high mammographic density and tumor tissues. Cancer Discov (2012) 2.51
Loss of TGF-beta type II receptor in fibroblasts promotes mammary carcinoma growth and invasion through upregulation of TGF-alpha-, MSP- and HGF-mediated signaling networks. Oncogene (2005) 2.35
The roles of TGFβ in the tumour microenvironment. Nat Rev Cancer (2013) 2.35
Induction by transforming growth factor-beta1 of epithelial to mesenchymal transition is a rare event in vitro. Breast Cancer Res (2004) 2.33
A tale of two proteins: differential roles and regulation of Smad2 and Smad3 in TGF-beta signaling. J Cell Biochem (2007) 2.32
Transforming growth factor beta receptor type II inactivation induces the malignant transformation of intestinal neoplasms initiated by Apc mutation. Cancer Res (2006) 2.14
Increased malignancy of Neu-induced mammary tumors overexpressing active transforming growth factor beta1. Mol Cell Biol (2003) 1.99
Transforming growth factor beta (TGF-beta) and inflammation in cancer. Cytokine Growth Factor Rev (2009) 1.95
Gr-1+CD11b+ myeloid cells tip the balance of immune protection to tumor promotion in the premetastatic lung. Cancer Res (2010) 1.83
Transcriptional cooperation between the transforming growth factor-beta and Wnt pathways in mammary and intestinal tumorigenesis. Cancer Res (2007) 1.81
Overexpression of HER2 (erbB2) in human breast epithelial cells unmasks transforming growth factor beta-induced cell motility. J Biol Chem (2004) 1.72
TGF-beta receptor deletion in the renal collecting system exacerbates fibrosis. J Am Soc Nephrol (2010) 1.70
Abrogation of TGF-beta signaling enhances chemokine production and correlates with prognosis in human breast cancer. J Clin Invest (2009) 1.68
Transforming growth factor-beta regulates mammary carcinoma cell survival and interaction with the adjacent microenvironment. Cancer Res (2008) 1.64
Dual role of transforming growth factor beta in mammary tumorigenesis and metastatic progression. Clin Cancer Res (2005) 1.62
Transforming growth factor beta receptor type II inactivation promotes the establishment and progression of colon cancer. Cancer Res (2004) 1.62
Effect of IGF-I in the chondrogenesis of bone marrow mesenchymal stem cells in the presence or absence of TGF-beta signaling. J Bone Miner Res (2006) 1.55
TGF-beta signaling is essential for joint morphogenesis. J Cell Biol (2007) 1.51
Transgenic mice expressing a dominant-negative mutant type II transforming growth factor-beta receptor exhibit impaired mammary development and enhanced mammary tumor formation. Am J Pathol (2003) 1.46
Tgfbeta signaling is required for atrioventricular cushion mesenchyme remodeling during in vivo cardiac development. Development (2006) 1.38
A delicate balance: TGF-beta and the tumor microenvironment. J Cell Biochem (2007) 1.38
Proliferation of estrogen receptor-alpha-positive mammary epithelial cells is restrained by transforming growth factor-beta1 in adult mice. Am J Pathol (2005) 1.35
Transforming growth factor beta-regulated gene expression in a mouse mammary gland epithelial cell line. Breast Cancer Res (2003) 1.32
Transforming growth factor beta: tumor suppressor or promoter? Are host immune cells the answer? Cancer Res (2008) 1.31
Rare somatic cells from human breast tissue exhibit extensive lineage plasticity. Proc Natl Acad Sci U S A (2013) 1.31
No paradox, no progress: inverse cancer comorbidity in people with other complex diseases. Lancet Oncol (2011) 1.30
Enhanced hepatocyte growth factor signaling by type II transforming growth factor-beta receptor knockout fibroblasts promotes mammary tumorigenesis. Cancer Res (2007) 1.27
TGF-β receptor II loss promotes mammary carcinoma progression by Th17 dependent mechanisms. Cancer Discov (2011) 1.26
TGF-beta-induced RhoA and p160ROCK activation is involved in the inhibition of Cdc25A with resultant cell-cycle arrest. Proc Natl Acad Sci U S A (2003) 1.25
Activin receptor-like kinase 2 and Smad6 regulate epithelial-mesenchymal transformation during cardiac valve formation. Dev Biol (2005) 1.21
Inactivation of TGF-beta signaling in hepatocytes results in an increased proliferative response after partial hepatectomy. Oncogene (2005) 1.20
The loss of TGF-beta signaling promotes prostate cancer metastasis. Neoplasia (2003) 1.20
Gain or loss of TGFbeta signaling in mammary carcinoma cells can promote metastasis. Cell Cycle (2009) 1.19
Oncogenic function of a novel WD-domain protein, STRAP, in human carcinogenesis. Cancer Res (2006) 1.16
Stromally derived lysyl oxidase promotes metastasis of transforming growth factor-β-deficient mouse mammary carcinomas. Cancer Res (2013) 1.16
Transforming growth factor-beta signaling-deficient fibroblasts enhance hepatocyte growth factor signaling in mammary carcinoma cells to promote scattering and invasion. Mol Cancer Res (2008) 1.15
Disruption of bone morphogenetic protein receptor 2 (BMPR2) in mammary tumors promotes metastases through cell autonomous and paracrine mediators. Proc Natl Acad Sci U S A (2011) 1.14
Epidermal growth factor receptor plays a significant role in hepatocyte growth factor mediated biological responses in mammary epithelial cells. Cancer Biol Ther (2007) 1.14
Contributions by members of the TGFbeta superfamily to lens development. Int J Dev Biol (2004) 1.09
GFAP-Cre-mediated activation of oncogenic K-ras results in expansion of the subventricular zone and infiltrating glioma. Mol Cancer Res (2009) 1.09
Lack of transforming growth factor-β signaling promotes collective cancer cell invasion through tumor-stromal crosstalk. Breast Cancer Res (2012) 1.05
Rapamycin disrupts cyclin/cyclin-dependent kinase/p21/proliferating cell nuclear antigen complexes and cyclin D1 reverses rapamycin action by stabilizing these complexes. Cancer Res (2006) 1.04
Deletion of TGF-β signaling in myeloid cells enhances their anti-tumorigenic properties. J Leukoc Biol (2012) 1.00
Altered prostate epithelial development in mice lacking the androgen receptor in stromal fibroblasts. Prostate (2011) 1.00
p120-catenin is essential for terminal end bud function and mammary morphogenesis. Development (2012) 0.99
Tumors initiated by constitutive Cdk2 activation exhibit transforming growth factor beta resistance and acquire paracrine mitogenic stimulation during progression. Cancer Res (2007) 0.98
Erlotinib prolongs survival in pancreatic cancer by blocking gemcitabine-induced MAPK signals. Cancer Res (2013) 0.96
Inflammatory bowel disease-associated colorectal cancer: proctocolectomy and mucosectomy do not necessarily eliminate pouch-related cancer incidences. Int J Colorectal Dis (2011) 0.95